Sort   by:  
 Page size 
MetabolomicsFirst-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failure

Diminished hepatocyte regeneration is a key feature of acute and chronic liver diseases and after extended liver resections, resulting in the inability to maintain or restore a sufficient functional liver mass. Therapies to restore hepatocyte regeneration are lacking, making liver transplantation...

2024-09-23 | MTBLS9434 | MetaboLights
MetabolomicsA comprehensive multiomic analysis reveals metabolic reprogramming underlying human Fontan-associated liver disease

BACKGROUND: Single ventricle congenital heart disease (SVCHD) is a severe form of cardiac malformation in which there is only one functional ventricle. The Fontan operation is the current standard of care for SVCHD. Almost all patients who have undergone the Fontan operation develop liver fibrosi...

2024-12-13 | MTBLS10782 | MetaboLights
MetabolomicsDeficient Endoplasmic Reticulum-Mitochondrial Phosphatidylserine Transfer Causes Liver Disease
Non-alcoholic fatty liver is the most common liver disease worldwide. Here, we show that the mitochondrial protein mitofusin 2 (Mfn2) protects against liver disease. Reduced Mfn2 expression was detected in liver biopsies from patients with non-alcoholic steatohepatitis (NASH). Moreover, reduced Mfn2...
2018-01-25 | MTBLS600 | MetaboLights
MetabolomicsGenome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD) is a major risk factor leading to chronic liver disease and type 2 diabetes. Here we chart liver metabolic activity and functionality in NAFLD by integrating global transcriptomic data, from human liver biopsies, and metabolic flux data, measured across the ...
2016-12-15 | MTBLS298 | MetaboLights
MetabolomicsGlobal 13C tracing and metabolic flux analysis of intact human liver tissue ex vivo
Liver metabolism is central to human physiology and influences the pathogenesis of common metabolic diseases. Yet, our understanding of human liver metabolism remains incomplete, with much of current knowledge based on animal or cell culture models that do not fully recapitulate human physiology. He...
2024-07-23 | MTBLS10481 | MetaboLights
MetabolomicsLipid Droplet Inhibitors for Disrupting Lipid Accumulation in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Excessive lipid droplet accumulation in hepatocytes drives the progression of metabolic dysfunction-associated steatotic liver disease (MASLD), often leading to inflammation and fibrosis. As obesity and metabolic syndrome rise, MASLD has become a global concern, spurring research into effective trea...
2025-07-17 | MTBLS12359 | MetaboLights
ProteomicsGlycoPCT: quantitative glycoproteomics based on pressure cycling technology reveals distinctive N-glycosylation in human liver with non-alcoholic fatty liver disease
Protein N-glycosylation plays a crucial role in the human liver, impacting key functions like hepatocyte lipid metabolism hepatocyte apoptosis, and inflammatory response. Despite its significance, the site-specific N-glycosylation patterns and their variations of liver biosy samples between healthy ...
ORGANISM(S): Homo Sapiens 
2024-07-04 | PXD053626 |
TranscriptomicsTranscriptome patterns for Acute Cellular Rejection in Recipients with Recurrent Hepatitis C after Liver Transplantation
The histological evaluation of liver via biopsy remains as the standard for the diagnosis of both acute cellular rejection (ACR) and recurrent hepatitis C (RHC) after liver transplantation. Nevertheless, it is often difficult to diagnose ACR in HCV-positive recipients because of common co-existing a...
ORGANISM(S): Homo sapiens 
2010-05-15 | E-GEOD-13440 | biostudies-arrayexpress
MetabolomicsProtective Effects of Cordycepin against Oxaliplatin-Associated Drug-Induced Fatty Liver Disease and Preliminary Mechanistic Insights

Oxaliplatin (OXA) is a chemotherapeutic agent used to treat multiple malignancies. Although it predominantly causes hepatic sinusoidal obstruction syndrome, it also induces drug-induced fatty liver disease (DIFLD) via lipid metabolic dysregulation and oxidative stress, which persists post-cessati...

2025-09-04 | MTBLS12938 | MetaboLights
MetabolomicsMulti-omic profiles of human nonalcoholic fatty liver disease tissue highlight heterogenic phenotypes
Non-alcoholic fatty liver disease (NAFLD) is a consequence of sedentary life style and high fat diets with an estimated prevalence of about 30% in western countries. It is associated with insulin resistance, obesity, glucose intolerance and drug toxicity. Additionally, polymorphisms in, e.g. APOC3, ...
2015-12-07 | MTBLS174 | MetaboLights
Sort   by:  
 Page size